Aveo, former execs reach $15M settlement with shareholders over 2013 drug rejection
Investors had accused the Cambridge biotech and the former executives of concealing issues with a kidney cancer drug before it was rejected.
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Max Stendahl Source Type: news
More News: American Health | Biotechnology | Cancer | Cancer & Oncology | Health Management | Kidney Cancer | Urology & Nephrology